GlassScriptPhysician profile
Robert Adam Young
NPI 1366857807
$5,393.53
in general payments reported to CMS, 2019-2025
19 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $162 · 2021: $534 · 2022: $786 · 2023: $937 · 2024: $664 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,435.98 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $1,282.95 | 2019-2025 | Precision7, Total30, Precision 1 |
| Coopervision INC. | $488.15 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $286.78 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $250.75 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $238.95 | 2019-2020 | |
| Oyster Point Pharma, INC. | $230.21 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $186.30 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $157.95 | 2021-2024 | |
| Tarsus Pharmaceuticals, INC. | $141.77 | 2025 | Xdemvy |
| Glaukos Corporation | $135.37 | 2025 | Photrexa Viscous and Photrexa |
| Abbvie INC. | $125.00 | 2023 | Durysta |
| Harrow Eye, LLC | $124.99 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $120.79 | 2021 | |
| Allergan, INC. | $106.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $31.23 | 2025 | Clarus |
| Astellas Pharma US INC | $20.96 | 2024 | Izervay |
| Sight Sciences, INC. | $15.23 | 2022 | |
| Biotissue Holdings INC. | $13.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.